Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Biohaven - The Untold Story

Patients Already in Biohaven Epilepsy Trials Keep Dosing as FDA Pauses New Enrollment Over a Rodent Finding

Patients Already in Biohaven Epilepsy Trials Keep Dosing as FDA Pauses New Enrollment Over a Rodent Finding

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer To Pay Million In Kickback Scheme Settlement

Pfizer settles million over kickbacks for Nurtec ODT prescriptions; whistleblower rewarded.

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

New Migraine Drugs No Better Than Cheap Painkillers: Big Study

Migraine drugs can represent big money for pharmaceutical firms, as shown when Pfizer acquired Biohaven -- which developed rimegepant -- for more than $10 billion in 2022.

inkl

Read news from The Economist, FT, and more,
with one subscription

Pfizer’s COVID cash powers a ‘marketing machine’ on the hunt for new supernovas

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions.

Tribune News Service

Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortune

Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortune

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Tisco Bank unit touts healthcare, biotech

Tisco Bank unit touts healthcare, biotech

Tisco Bank's wealth advisory unit suggests moving away from energy stocks to biotechnology and healthcare as several US economic indicators have signalled a higher risk of recession.

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion. Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

The Independent UK

European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine

European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine

European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.

Get all your
news in one place.

100's of premium titles.
One news app.

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Bank of America

Starboard Value

ClinicalTrialsgov

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,767 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play